Half-year report · HY

Period2025-07-01 → 2025-12-31
Filed2026-02-13
StandardJapan GAAP
ConsolidatedYes
Data checks14 of 14 passed
Key figures · 44
MetricValuePeriodScopeSource row
Revenue¥2.4bn2025-07-01 → 2025-12-31Cons.Net sales
Revenue¥4.8bn2024-07-01 → 2025-06-30Cons.Net sales (5-year summary)
Revenue¥2.7bn2024-07-01 → 2024-12-31Cons.Net sales
Operating income¥231m2025-07-01 → 2025-12-31Cons.Operating income
Operating income−¥203m2024-07-01 → 2024-12-31Cons.Operating income
Ordinary income¥238m2025-07-01 → 2025-12-31Cons.Ordinary income
Ordinary income−¥129m2024-07-01 → 2025-06-30Cons.Ordinary income loss (5-year summary)
Ordinary income−¥198m2024-07-01 → 2024-12-31Cons.Ordinary income
Profit before tax¥195m2025-07-01 → 2025-12-31Cons.Income before income taxes
Profit before tax−¥212m2024-07-01 → 2024-12-31Cons.Income before income taxes
Net income (owners)¥162m2025-07-01 → 2025-12-31Cons.Profit loss attributable to owners of parent
Net income (owners)−¥211m2024-07-01 → 2025-06-30Cons.Profit loss attributable to owners of parent (5-year summary)
Net income (owners)−¥222m2024-07-01 → 2024-12-31Cons.Profit loss attributable to owners of parent
Net income¥162m2025-07-01 → 2025-12-31Cons.Profit loss
Net income−¥222m2024-07-01 → 2024-12-31Cons.Profit loss
Total assets¥6.7bnat 2025-12-31Cons.Assets
Total assets¥6.8bnat 2025-06-30Cons.Assets
Total assets¥6.6bnat 2024-12-31Cons.Total assets (5-year summary)
Total liabilities¥612mat 2025-12-31Cons.Liabilities
Total liabilities¥775mat 2025-06-30Cons.Liabilities
Net assets / equity¥6.1bnat 2025-12-31Cons.Net assets
Net assets / equity¥6.0bnat 2025-06-30Cons.Net assets
Net assets / equity¥6.0bnat 2024-12-31Cons.Net assets (5-year summary)
Cash and deposits¥5.0bnat 2025-12-31Cons.Cash and deposits
Cash and deposits¥5.0bnat 2025-06-30Cons.Cash and deposits
Cash & equivalents¥5.0bnat 2025-12-31Cons.Cash and cash equivalents
Cash & equivalents¥5.0bnat 2025-06-30Cons.Cash and cash equivalents
Cash & equivalents¥4.6bnat 2024-12-31Cons.Cash and cash equivalents
Cash & equivalents¥4.8bnat 2024-06-30vCons.Cash and cash equivalents
Operating cash flow¥134m2025-07-01 → 2025-12-31Cons.Net cash provided by used in operating activities
Operating cash flow¥558m2024-07-01 → 2025-06-30Cons.Net cash provided by used in operating activities (5-year summary)
Operating cash flow¥98m2024-07-01 → 2024-12-31Cons.Net cash provided by used in operating activities
Investing cash flow¥71m2025-07-01 → 2025-12-31Cons.Net cash provided by used in investment activities
Investing cash flow−¥389m2024-07-01 → 2025-06-30Cons.Net cash provided by used in investing activities (5-year summary)
Investing cash flow−¥324m2024-07-01 → 2024-12-31Cons.Net cash provided by used in investment activities
Financing cash flow−¥139m2025-07-01 → 2025-12-31Cons.Net cash provided by used in financing activities
Financing cash flow−¥214,0002024-07-01 → 2025-06-30Cons.Net cash provided by used in financing activities (5-year summary)
Financing cash flow−¥172,0002024-07-01 → 2024-12-31Cons.Net cash provided by used in financing activities
EPS (basic)¥6.192025-07-01 → 2025-12-31Cons.Basic earnings loss per share (5-year summary)
EPS (basic)¥-8.052024-07-01 → 2025-06-30Cons.Basic earnings loss per share (5-year summary)
EPS (basic)¥-8.52024-07-01 → 2024-12-31Cons.Basic earnings loss per share (5-year summary)
Equity ratio90.8%at 2025-12-31Cons.Equity to asset ratio (5-year summary)
Equity ratio88.4%at 2025-06-30Cons.Equity to asset ratio (5-year summary)
Equity ratio91.3%at 2024-12-31Cons.Equity to asset ratio (5-year summary)

Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.

Segments · 51
SegmentItemPeriodValue
Reconciling Itemsreconcilingrevenue2025-07-01 → 2025-12-31−¥16m
Reconciling Itemsreconcilingrevenue external2025-07-01 → 2025-12-31¥900,000
Reconciling Itemsreconcilingrevenue intersegment2025-07-01 → 2025-12-31−¥17m
Reconciling Itemsreconcilingsegment profit2025-07-01 → 2025-12-31−¥174m
Clinical Evidence Servicereportable segmentrevenue2025-07-01 → 2025-12-31¥131m
Clinical Evidence Servicereportable segmentrevenue external2025-07-01 → 2025-12-31¥131m
Clinical Evidence Servicereportable segmentsegment profit2025-07-01 → 2025-12-31¥11m
Functional Cosmetic Retailingreportable segmentrevenue2025-07-01 → 2025-12-31¥726m
Functional Cosmetic Retailingreportable segmentrevenue external2025-07-01 → 2025-12-31¥725m
Functional Cosmetic Retailingreportable segmentrevenue intersegment2025-07-01 → 2025-12-31¥919,000
Functional Cosmetic Retailingreportable segmentsegment profit2025-07-01 → 2025-12-31¥83m
Functional Food Retailingreportable segmentrevenue2025-07-01 → 2025-12-31¥933m
Functional Food Retailingreportable segmentrevenue external2025-07-01 → 2025-12-31¥926m
Functional Food Retailingreportable segmentrevenue intersegment2025-07-01 → 2025-12-31¥7m
Functional Food Retailingreportable segmentsegment profit2025-07-01 → 2025-12-31¥217m
Functional Material Developmentreportable segmentrevenue2025-07-01 → 2025-12-31¥180m
Functional Material Developmentreportable segmentrevenue external2025-07-01 → 2025-12-31¥171m
Functional Material Developmentreportable segmentrevenue intersegment2025-07-01 → 2025-12-31¥9m
Functional Material Developmentreportable segmentsegment profit2025-07-01 → 2025-12-31¥19m
Health Care Support Servicereportable segmentrevenue2025-07-01 → 2025-12-31¥460m
Health Care Support Servicereportable segmentrevenue external2025-07-01 → 2025-12-31¥460m
Health Care Support Servicereportable segmentsegment profit2025-07-01 → 2025-12-31¥75m
—segment totalrevenue2025-07-01 → 2025-12-31¥2.4bn
—segment totalrevenue external2025-07-01 → 2025-12-31¥2.4bn
—segment totalrevenue intersegment2025-07-01 → 2025-12-31¥17m
—segment totalsegment profit2025-07-01 → 2025-12-31¥404m
Reconciling Itemsreconcilingrevenue2024-07-01 → 2024-12-31−¥14m
Reconciling Itemsreconcilingrevenue external2024-07-01 → 2024-12-31¥900,000
Reconciling Itemsreconcilingrevenue intersegment2024-07-01 → 2024-12-31−¥15m
Reconciling Itemsreconcilingsegment profit2024-07-01 → 2024-12-31−¥159m
Clinical Evidence Servicereportable segmentrevenue2024-07-01 → 2024-12-31¥152m
Clinical Evidence Servicereportable segmentrevenue external2024-07-01 → 2024-12-31¥152m
Clinical Evidence Servicereportable segmentsegment profit2024-07-01 → 2024-12-31¥19m
Functional Cosmetic Retailingreportable segmentrevenue2024-07-01 → 2024-12-31¥751m
Functional Cosmetic Retailingreportable segmentrevenue external2024-07-01 → 2024-12-31¥751m
Functional Cosmetic Retailingreportable segmentsegment profit2024-07-01 → 2024-12-31¥25m
Functional Food Retailingreportable segmentrevenue2024-07-01 → 2024-12-31¥1.2bn
Functional Food Retailingreportable segmentrevenue external2024-07-01 → 2024-12-31¥1.2bn
Functional Food Retailingreportable segmentrevenue intersegment2024-07-01 → 2024-12-31¥4m
Functional Food Retailingreportable segmentsegment profit2024-07-01 → 2024-12-31−¥132m
Functional Material Developmentreportable segmentrevenue2024-07-01 → 2024-12-31¥183m
Functional Material Developmentreportable segmentrevenue external2024-07-01 → 2024-12-31¥173m
Functional Material Developmentreportable segmentrevenue intersegment2024-07-01 → 2024-12-31¥11m
Functional Material Developmentreportable segmentsegment profit2024-07-01 → 2024-12-31¥3m
Health Care Support Servicereportable segmentrevenue2024-07-01 → 2024-12-31¥393m
Health Care Support Servicereportable segmentrevenue external2024-07-01 → 2024-12-31¥393m
Health Care Support Servicereportable segmentsegment profit2024-07-01 → 2024-12-31¥39m
—segment totalrevenue2024-07-01 → 2024-12-31¥2.7bn
—segment totalrevenue external2024-07-01 → 2024-12-31¥2.7bn
—segment totalrevenue intersegment2024-07-01 → 2024-12-31¥15m
—segment totalsegment profit2024-07-01 → 2024-12-31−¥45m

Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.

All source rows · 465
ItemContextValueUnit
Operating incomeInterimDuration_jpcrp040300-ssr_E05367-000ClinicalEvidenceServiceReportableSegmentsMember10767000JPY
Operating incomeInterimDuration_jpcrp040300-ssr_E05367-000HealthCareSupportServiceReportableSegmentsMember74855000JPY
Operating incomeInterimDuration_jpcrp040300-ssr_E05367-000FunctionalCosmeticRetailingReportableSegmentsMember82871000JPY
Operating incomeInterimDuration_jpcrp040300-ssr_E05367-000FunctionalFoodRetailingReportableSegmentsMember217090000JPY
Operating incomeInterimDuration_jpcrp040300-ssr_E05367-000FunctionalMaterialDevelopmentReportableSegmentsMember18878000JPY
Operating incomeInterimDuration_ReportableSegmentsMember404463000JPY
Operating incomeInterimDuration_ReconcilingItemsMember-173616000JPY
Operating incomeInterimDuration230846000JPY
Document title cover pageFilingDateInstant
Original text (Japanese)半期報告書
Clause of stipulation cover pageFilingDateInstant
Original text (Japanese)金融商品取引法第24条の5第1項の表の第1号
Place of filing cover pageFilingDateInstant
Original text (Japanese)近畿財務局長
Filing date cover pageFilingDateInstant2026-02-13
Semi annual accounting period cover pageFilingDateInstant
Original text (Japanese)第32期中(自 2025年7月1日 至 2025年12月31日)
Company name cover pageFilingDateInstant
Original text (Japanese)株式会社総医研ホールディングス
Company name in english cover pageFilingDateInstantSoiken Holdings Inc.
Title and name of representative cover pageFilingDateInstant
Original text (Japanese)代表取締役社長  角田 真佐夫
Address of registered headquarter cover pageFilingDateInstant
Original text (Japanese)大阪府豊中市新千里東町一丁目4番2号
Telephone number address of registered headquarter cover pageFilingDateInstant06(6871)8888
Name of contact person address of registered headquarter cover pageFilingDateInstant
Original text (Japanese)取締役財務部長  奥野 貴人
Nearest place of contact cover pageFilingDateInstant
Original text (Japanese)大阪府豊中市新千里東町一丁目4番2号
Telephone number nearest place of contact cover pageFilingDateInstant06(6871)8888
Name of contact person nearest place of contact cover pageFilingDateInstant
Original text (Japanese)取締役財務部長  奥野 貴人
Place for public inspection cover page (text)FilingDateInstantText · Plus
Edinet codeFilingDateInstantE05367
Fund codeFilingDateInstant-
Security codeFilingDateInstant23850
Filer name in japaneseFilingDateInstant
Original text (Japanese)株式会社総医研ホールディングス
Filer name in englishFilingDateInstantSoiken Holdings Inc.
Fund name in japaneseFilingDateInstant-
Fund name in englishFilingDateInstant-
Cabinet office ordinanceFilingDateInstant
Original text (Japanese)企業内容等の開示に関する内閣府令
Document typeFilingDateInstant
Original text (Japanese)第四号の三様式
Accounting standardsFilingDateInstantJapan GAAP
Whether consolidated financial statements are preparedFilingDateInstanttrue
Industry code when consolidated financial statements are prepared in accordance with industry specific regulationsFilingDateInstantCTE
Industry code when financial statements are prepared in accordance with industry specific regulationsFilingDateInstant-
Current fiscal year start dateFilingDateInstant2025-07-01
Current period end dateFilingDateInstant2025-12-31
Type of current periodFilingDateInstantHY
Current fiscal year end dateFilingDateInstant2026-06-30
Previous fiscal year start dateFilingDateInstant2024-07-01
Comparative period end dateFilingDateInstant2024-12-31
Previous fiscal year end dateFilingDateInstant2025-06-30
Next fiscal year start dateFilingDateInstant-
End date of quarterly or semi annual period of next fiscal yearFilingDateInstant-
Amendment flagFilingDateInstantfalse
Identification of document subject to amendmentFilingDateInstant-
Report amendment flagFilingDateInstantfalse
Xbrl amendment flagFilingDateInstantfalse
Business results of group (text)FilingDateInstantText · Plus

Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.

Data checks · 14 of 14 passed
balance sheet identityconsolidated 2025-06-30pass rounding
balance sheet identityconsolidated 2025-12-31pass
dei present pass
period resolution pass
statement vs summary · net assetsconsolidated 2025-06-30pass
statement vs summary · net assetsconsolidated 2025-12-31pass
statement vs summary · net income attributable to parentconsolidated 2024-07-01/2024-12-31pass
statement vs summary · net income attributable to parentconsolidated 2025-07-01/2025-12-31pass
statement vs summary · operating cash flowconsolidated 2024-07-01/2024-12-31pass
statement vs summary · operating cash flowconsolidated 2025-07-01/2025-12-31pass
statement vs summary · revenueconsolidated 2024-07-01/2024-12-31pass
statement vs summary · revenueconsolidated 2025-07-01/2025-12-31pass
statement vs summary · total assetsconsolidated 2025-06-30pass
statement vs summary · total assetsconsolidated 2025-12-31pass